Weak Support for Malaria Vaccine

The World Health Organization recommends more pilot trials.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PIXABAY, PHOTOLIZMThe first vaccine against malaria received a tepid review from global health officials last week (October 23). A World Health Organization (WHO) committee announced its support last week for a pilot roll-out, rather than mass immunization.

Of concern, said Jon Abramson, chair of the WHO advisory committee, is making sure children get all four shots. “What we are recommending is that before we have widespread use of this vaccine—and we wouldn’t necessarily use it in a very low incidence area, but in all medium and high areas—that we know that we can get that fourth dose in,” Abramson told reporters (via Reuters).

The vaccine is already considered a mediocre performer. Earlier this year, a study found it reduces malaria cases in children by up to 36 percent. “Still, this modest effect could save hundreds of lives each year because malaria kills nearly half a million people annually, most of whom are children in sub-Saharan Africa,” Nature News reported last week (October ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

DNA and pills, conceptual illustration of the relationship between genetics and therapeutic development

Multiplexing PCR Technologies for Biopharmaceutical Research

Thermo Fisher Logo
Discover how to streamline tumor-infiltrating lymphocyte production.

Producing Tumor-infiltrating Lymphocyte Therapeutics

cytiva logo

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery